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Much progress has been made over the past two decades in the treatment of severe acute
brain injury, including traumatic brain injury and subarachnoid hemorrhage, resulting in a
higher proportion of patients surviving with better outcomes.This has arisen from a combi-
nation of factors.These include improvements in procedures at the scene (pre-hospital) and
in the hospital emergency department, advances in neuromonitoring in the intensive care
unit, both continuously at the bedside and intermittently in scans, evolution and refinement
of protocol-driven therapy for better management of patients, and advances in surgical pro-
cedures and rehabilitation. Nevertheless, many patients still experience varying degrees of
long-term disabilities post-injury with consequent demands on carers and resources, and
there is room for improvement. Biomarkers are a key aspect of neuromonitoring. A broad
definition of a biomarker is any observable feature that can be used to inform on the state
of the patient, e.g., a molecular species, a feature on a scan, or a monitoring characteristic,
e.g., cerebrovascular pressure reactivity index. Biomarkers are usually quantitative mea-
sures, which can be utilized in diagnosis and monitoring of response to treatment.They are
thus crucial to the development of therapies and may be utilized as surrogate endpoints in
Phase II clinical trials.To date, there is no specific drug treatment for acute brain injury, and
many seemingly promising agents emerging from pre-clinical animal models have failed in
clinical trials. Large Phase III studies of clinical outcomes are costly, consuming time and
resources. It is therefore important that adequate Phase II clinical studies with informative
surrogate endpoints are performed employing appropriate biomarkers. In this article, we
review some of the available systemic, local, and imaging biomarkers and technologies
relevant in acute brain injury patients, and highlight gaps in the current state of knowledge.
Keywords: acute brain injury (human), biomarkers, cerebral energy metabolism, cell death, inflammation, blood–
brain barrier, multimodality monitoring, imaging
INTRODUCTION
The ictus–the catastrophic event of severe acute brain injury–is
followed over the ensuing hours and days by a secondary cascade
of pathological processes that can exacerbate neuronal injury and
worsen outcome. These secondary changes are potential targets
for therapy. Although progress has been made, many patients still
Abbreviations: ABP, arterial blood pressure; ADC, apparent diffusion coefficient;
ARDS, acute respiratory distress syndrome; ATP, adenosine triphosphate; BTF,
Brain Trauma Foundation; CMRglc, cerebral metabolic rate of glucose; CMRO2,
cerebral metabolic rate of oxygen; CNS, central nervous system; CPP, cerebral per-
fusion pressure; CSF, cerebrospinal fluid; CT, computed tomography; DCI, delayed
cerebral ischemia; DIND, delayed ischemic neurological deficits; DTI, diffusion
tensor imaging; DWI, diffusion weighted imaging; EEG, electroencephalography;
ET, endothelin; FA, fractional anisotropy; FDG, 18F-fluorodeoxyglucose; FLAIR,
fluid-attenuated inversion recovery; GABA, gamma-aminobutyric acid; GCS, Glas-
gow coma scale score; GFAP, glial fibrillary acidic protein; GOS, Glasgow outcome
scale score; GE, gradient echo; GRE, gradient recalled echo; HPLC, high perfor-
mance liquid chromatography; ICH, intracranial hemorrhage; ICP, intracranial
experience varying degrees of long-term disabilities post-injury
with consequent demands on carers and resources, and there is
room for improvement (1).
Significant advances in treatment over the past two decades
for traumatic brain injury (TBI) and subarachnoid hemorrhage
(SAH) has led to more patients surviving with better outcomes,
pressure; IL, interleukin; i.v., intravenous; LDH, lactate dehydrogenase; LPR, lac-
tate/pyruvate ratio; MMP, matrix metalloprotease; MRI, magnetic resonance imag-
ing; MRS, magnetic resonance spectroscopy; NAA, N -acetylaspartate; NAAG, N -
acetylaspartylglutamate; NAD+, nicotine adenine dinucleotide (oxidized form);
NADH, nicotine adenine dinucleotide (reduced form); NMR, nuclear magnetic res-
onance; NSE, neuron-specific enolase; PbtO2, brain tissue oxygen tension; PCR,
phosphocreatine; PET, positron emission tomography; Pi, inorganic phosphate;
POCE, proton-observe carbon edited; PPP, pentose phosphate pathway; PRx, pres-
sure reactivity index; ROI, region(s) of interest; SAH, subarachnoid hemorrhage;
SD, spreading depolarizations; SWI, susceptibility-weighted imaging; TAI, traumatic
axonal injury; TBI, traumatic brain injury; TCA cycle, tricarboxylic acid cycle; TCD,
transcranial Doppler; TNF, tumor necrosis factor.
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due to a combination of factors. These include evolution of
evidence-based guidelines for TBI management (2), growing
recognition of the benefits of managing severe TBI patients in
neuroscience centers and procedures for safe transfer of patients
to such centers, better triage and assessment of patients on admis-
sion, including computed tomography (CT) scans, better neu-
romonitoring in the neurocritical care unit, both continuously
at the bedside [e.g., intracranial pressure (ICP) and brain tis-
sue oxygen monitoring] and intermittently in scans [e.g., CT and
magnetic resonance imaging (MRI)], evolution and refinement of
protocol-driven therapy for better management of patients, and
improvements in surgical procedures and rehabilitation (1). Even
so, TBI remains the leading cause of mortality and disability in
young people in high-income countries (3). Moreover, TBI is ris-
ing in developing countries largely due to wider use of motor
vehicles, while a shift toward older age of patients with TBI due
to falls is occurring, especially in high-income countries (3, 4).
While SAH can sometimes result from trauma (head injury), it
can also occur non-traumatically, usually as a result of rupture of
intracranial aneurysms in about 80–85% of non-traumatic SAH
(5, 6). Aneurysmal SAH carries a high risk of complications, a
high degree of dependency in survivors, and most SAH patients
are under 60 years of age (5, 6).
Biomarkers are a key aspect of neuromonitoring. A broad def-
inition of a biomarker is any observable feature that can be used
to inform on the state of the patient, e.g., a molecular species,
a feature on a scan, or a monitoring characteristic, e.g., cere-
brovascular pressure reactivity index (PRx). Examples are tab-
ulated (Table 1). Biomarkers are usually quantitative measures,
which can be utilized in diagnosis, prognosis, monitoring evo-
lution of injury and recovery, and response to treatments (7).
They are thus crucial to the development of therapies in many
pathological states and may be utilized as surrogate endpoints
in Phase II clinical trials. To date, there is no specific drug treat-
ment for acute brain injury, and many seemingly promising agents
emerging from pre-clinical animal models have failed in clini-
cal trials (7). Part of the discrepancy may be due to the much
greater heterogeneity of clinical TBI compared with the highly
standardized conditions of experimental models (7). To have
enough statistical power, Phase III randomized controlled tri-
als of clinical outcomes require large numbers of patients and
are costly, consuming much time and resources. Moreover, they
may divert crucial numbers of patients away from other clini-
cal trials. Before deciding to embark on Phase III ventures, it is
important that adequate Phase II clinical studies with informative
surrogate endpoints are performed employing appropriate bio-
markers. In this article, we review some of the available systemic,
local, and imaging biomarkers and technologies relevant in acute
brain injury patients, and highlight gaps in the current state of
knowledge.
BIOMARKERS OF INTRACRANIAL DYNAMICS
Raised ICP or inadequate cerebral perfusion pressure [CPP, which
is calculated as mean arterial blood pressure (ABP) minus ICP]
is one of the most frequent cases of secondary ischemic brain
insults after TBI. Example traces are shown in Figure 1. Absolute
thresholds for intracranial hypertension and hypoperfusion are
known, and they are based on statistical evaluation of large samples
of patients, but most probably they are individual- and time-
dependent. “Optimal CPP strategy” (23) indicated a possible
solution for individualization of CPP management target, using
continuous assessment of cerebrovascular reactivity (24, 25). This
can be translated to the concept of “optimal mean arterial pres-
sure” in clinical scenarios where raised ICP is not a meaningful
factor, e.g., cardiopulmonary bypass surgery (26) and in care of
premature newborns (27).
In TBI, monitoring and manipulation of ICP and CPP com-
prise a cornerstone of intensive care. Often, the same principles
of management are extrapolated to other, non-traumatic, acute
brain injuries where intracranial compliance and pressure-flow
dynamics may be compromised. Despite the lack of level-1 evi-
dence, the Brain Trauma Foundation (BTF) guidelines advocate
the implementation of therapies when ICP exceeds the range of
20–25 mmHg and to maintain a CPP in the range of 50–70 mmHg
(with a recommended goal of 60 mmHg) (28).
Recognition of the strong association between intracranial
hypertension and systemic hypotension with increased morbid-
ity and mortality in patients with TBI has been established, based
among others, on landmark studies from the Traumatic Coma
Data Bank (29).
The goal of CPP≥ 70 mmHg or the practice of “indiscriminate”
CPP augmentation fell out of favor after a demonstration of lack
of clinical outcome benefit coupled with an increased incidence of
complications and particularly the acute respiratory distress syn-
drome (ARDS). Yet another aspect of the CPP debate is the Lund
concept or the “ICP and microperfusion-guided management” as
proposed by the University of Lund, Sweden (30). Proponents of
this strategy focus on ICP control (rather than CPP), maintenance
of intravascular volume with the use of colloids, and accept a lower
CPP to avoid exacerbating cerebral edema by an increase of water
leak through capillaries’ walls into brain.
Intracranial hypertension has been closely linked to adverse
outcomes after; nevertheless there remain no large randomized
trials that directly compare ICP treatment thresholds. Data from
observational studies and non-controlled series have suggested
thresholds ranging from 20 to 25 mmHg. The BTF’s latest guide-
line statement has identified a lack of level-1 evidence and offered,
as a level-2, the treatment threshold of 20 mmHg based mainly
on the largest available, prospective, observational study (31). In
the same document, it is recognized that rather than accepting
a generic, absolute ICP threshold, an attempt should be made
to individualize thresholds based on patient characteristics, other
critical parameters, and on a risk-benefit consideration of treat-
ing ICP values (32). Similar to individual target in CPP-oriented
therapy, we can define patient-specific, pressure reactivity-guided
ICP thresholds by graphing the relationship between ICP and PRx
(32). The PRx is a moving correlation coefficient of ICP and mean
ABP (mABP), and reflects status of cerebral vascular autoreg-
ulation. Positive PRx values imply that increases in mABP are
positively associated with increases in ICP, suggesting autoregula-
tory impairment, whereas negative PRx values indicate preserved
vascular reactivity, with vasoconstriction and decrease in ICP in
relation to surges in mABP. The PRx has been previously validated
against other indices of cerebral autoregulation (25), and is related
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Table 1 | Examples of biomarker methodology in human brain.
Biomarkers in human brain Technique Extent of
measurement
Timeframe (and frequency) Invasive?
Intracranial dynamics: ICP, CPP, ABP, PRx,
PbtO2 (8–10)
Sensors for pressure
and O2 concentration
ICP–global
PbtO2–
regional/focal
100–0.1 Hz. Multi-day.
Often expressed averaged
over time (e.g., hourly)
Yes (insertion of probes into
brain)
Net changes (import or export) by brain
for glucose and lactate (11)
Arteriovenous
difference
Global Multi-day (sampling twice
daily)
Yes (insertion of arterial line
and jugular venous catheter)
Brain extra-cellular concentrations of
small molecules (e.g., glucose, lactate,
pyruvate, glutamate, and glycerol) (8)
Microdialysis Focal Multi-day (hourly vial
changes)
Yes (insertion of catheter into
brain)
Regional cerebral metabolic rate of
glucose (CMRglc) or oxygen (CMRO2)
(12, 13)
PET Global and
regional
Usually single scan session
(<1 h), sometimes repeated
after a few days
Yes (i.v. injection of
radioactivity with short
half-life)
Cerebral inflammation: presence of
activated microglia (ligand PK11195)
(14, 15)
PET Global and
regional
Usually single scan session
(<1 h), sometimes repeated
after a few days
Yes (i.v. injection of
radioactivity with short
half-life)
Brain extra-cellular proteins<100 kDa
(e.g., cytokines and chemokines) (16)
Microdialysis Focal Multi-day (hourly vial
changes)–usually several
hours pooled (e.g., 4–8×1 h
vials) for analysis
Yes (insertion of catheter into
brain)
Small molecules in brain tissue (e.g.,
NAA, creatine, choline, myo-inositol,
glutamate and glutamine, GABA,
lactate) (17)
1H-MRS Regional and
voxel
Usually single scan session
(<1 h), sometimes repeated
after a few days
No
Phosphorus-containing small molecules
in brain tissue (e.g., ATP,
phosphocreatine, inorganic phosphate)
and brain intracellular pH (18)
31P MRS Regional and
voxel
Usually single scan session
(<1 h), sometimes repeated
after a few days
No
13C-labeling in metabolites in brain tissue
(e.g., glutamate and glutamine) for
calculating TCA cycle rate, other
13C-labeled species also detectable (e.g.,
GABA, aspartate, NAA) (19)
13C MRS Regional and
voxel
Usually single scan session
(ca. 2 h)
Moderately (i.v. bolus and
infusion of stable-isotope
13C-labeled substrate, e.g.,
glucose)
13C-labeling patterns in metabolites
detected extracellularly (e.g., glutamine
or lactate) diagnostic for biochemical
pathways such as TCA cycle, glycolysis,
PPP (20, 21)
13C-labeled
microdialysis
Focal Typically 24 h (24×1 h vials
pooled)
Yes (insertion of catheter into
brain, perfused with solution
of stable-isotope 13C-labeled
substrate, e.g., glucose,
lactate, or acetate)
Table adapted from Jalloh et al. (22).
ABP, arterial blood pressure; ATP, adenosine triphosphate; CMRglc, cerebral metabolic rate of glucose; CMRO2, cerebral metabolic rate of oxygen; CPP, cerebral
perfusion pressure; GABA, gamma-aminobutyric acid; ICP, intracranial pressure; i.v., intravenous; MRS, magnetic resonance spectroscopy; NAA, N-acetylaspartate;
PbtO2, brain tissue oxygen concentration; PET, positron emission tomography; PPP, pentose phosphate pathway; PRx, pressure reactivity index.
to outcome (10). PRx may be averaged over time, but also across
different CPP levels, giving “optimal CPP” values, and across ICP,
giving individual “ICP critical thresholds.”
Another, unexplored concept is to use biochemical mark-
ers to establish individual thresholds for rising ICP and falling
CPP. Biochemical markers of raised ICP and decreased CPP are
primary markers of cerebral ischemia. Most established is the
lactate/pyruvate ratio (LPR) measured in brain microdialysates.
Timofeev et al. found that LPR, glucose, ICP, and PRx are inde-
pendent and significant predictors of mortality [along with age
and admission Glasgow coma scale score (GCS)] (8). Examples
of LPR deterioration that are coincidental with worsening of PRx,
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FIGURE 1 | Example of monitoring (for 4 days) in a road traffic accident
victim (aged 22 years): intracranial pressure (ICP), cerebral perfusion
pressure (CPP), pressure reactivity index (PRx), brain tissue oxygenation
(PbtO2), and lactate/pyruvate ratio (LPR). Initial GCS was 13 and
deteriorated quickly to 7. Patient had never daily averaged ICP above
20 mmHg, CPP was above 70 mmHg all the time. On day 2 after injury,
pressure reactivity (PRx) deteriorated (marker 1, this can be also read by “risk
plot,” where PRx is color coded: green–good reactivity, red–deteriorated
reactivity) and lactate/pyruvate ratio exceeded 25 and 30 later. On day 4, the
patient improved (good CT scan), lactate/pyruvate ratio decreased, and PRx
improved (marker 2). The patient was weaned uneventfully from the ventilator
and successfully extubated shortly afterward. This example shows that
lactate/pyruvate ratio and PRx may be markers of deterioration, adding clinical
information independently of ICP and CPP.
but not explained by rising ICP or falling CPP are presented in
Figure 1. In a swine model of intracranial hemorrhage (ICH),
PRx correlated with LPR and glutamate level (33). Glycerol and
LPR associated with pressure reactivity only in perilesional tissue
after TBI (9). A spontaneous ICH study (34) has suggested similar
association. Both PRx and LPR show time-dependent improve-
ment after severe head injury–on average they both recover after
5 days (35).
Serum and cerebrospinal fluid (CSF) content of IL-8 and,
to a lesser extent, tumor necrosis factor (TNF)-α demonstrated
the most promise to be candidate serum markers of impending
intracranial hypertension and cerebral hypoperfusion after TBI
with proteomic mapping (36). In different analysis, S-100β lev-
els in CSF were associated with high ICP and low CPP over a full
week of ICP monitoring (37). Other neuroscientists suggested that
serum IL-6 can be used for the differential diagnosis of elevated
ICP in isolated TBI (38). Initial serum ceruloplasmin/copper levels
may have diagnostic value in predicting patients at risk for devel-
oping high ICP after TBI (39). Analysis of serum retinol binding
protein 4 levels at 24–36 h post-injury indicates it may predict sub-
sequent increases in ICP with a sensitivity of 86% and specificity
of 88% at 11.6µg/mL (40). In this study, the authors have identi-
fied 31 candidate biomarkers whose serum abundance was altered
after injury.
Intracranial dynamics biomarkers are important for moni-
toring not only TBI but also SAH (see later Section entitled
“Biomarkers of Cerebral Circulation in SAH”).
With further regard to TBI patient management, results were
published in 2012 from a randomized trial (BEST TRIP) that
enrolled 324 patients with severe TBI in South America, which
examined the clinical effectiveness of care using ICP monitor-
ing versus imaging and clinical examination-based monitoring
(41). The trial concluded that care focused on maintaining ICP
at 20 mmHg or less was not superior to care based on imag-
ing and clinical examination. However, it is important to note
that patients in both arms received tiered ICP-lowering thera-
pies, and a decompressive craniectomy was performed in 30% of
patients in each arm. Hence, the trial findings do not challenge the
belief that brain edema and raised ICP should be actively managed
after TBI.
In 2014, a consensus statement on the indications for ICP
monitoring has been published (42). This was designed as an
interim replacement for the BTF guidelines, as numerous spe-
cialists regarded the latter as not being explicit enough. Overall,
current clinical practice seems to accept the value of post-operative
ICP monitoring in severely head-injured patients.
EXTRA-CELLULAR BIOMARKERS OF BRAIN CHEMISTRY
MICRODIALYSIS BIOMARKERS OF ENERGY METABOLISM
The pathophysiology of TBI includes derangements to energy
metabolism, which are independent of ischemia and evolve over
the scale of hours and days (8, 43). Experimental studies suggest an
acute increase in glucose metabolism, which relates to disturbances
in ionic and neurochemical gradients (44–46). Clinical TBI studies
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demonstrate changes to glucose uptake and its subsequent metab-
olism (47–49). The degree of metabolic perturbation observed
after injury is affected by interventions and relates to clinical out-
come (8, 13, 50–53). Hence, biomarkers of energy metabolism
provide important information on the state of the brain-injured
patient.
Microdialysis, which allows the in vivo sampling of molecules
in the extra-cellular fluid of the human brain, is well suited to fol-
lowing energy metabolism. Early microdialysis studies in human
brain were conducted by Hillered et al. in patients undergoing
operations for brain tumors (54). Studies by Persson et al. pio-
neered microdialysis in TBI and SAH patients, where ICP was
measured in parallel with microdialysate levels of lactate, pyru-
vate (and LPR), hypoxanthine, glutamate, and several other amino
acids (55). These analyses were by high performance liquid chro-
matography (HPLC). Nowadays, clinical microdialysis analyzers
(which utilize enzymatic colorimetric assays on a micro-scale) are
commercially available for use at the bedside, and the analytes
that they measure, related to energy metabolism, include glucose,
lactate, pyruvate, glutamate, and glycerol. The brain is reliant on
a continuous source of glucose as an energy substrate, which it
uses almost exclusively under normal physiological conditions.
Inside the cytosol, glucose undergoes glycolysis to pyruvate, which
can be exported into the extra-cellular space and measured with
microdialysis, undergo conversion to acetyl-CoA and subsequent
metabolism via the mitochondrial tricarboxylic acid cycle (TCA
cycle), or be converted to lactate by the action of lactate dehydro-
genase (LDH). The TCA cycle results in the recycling of nicotine
adenine dinucleotide (oxidized form; NAD+) to nicotine adenine
dinucleotide (reduced form; NADH). The donation of electrons
by NADH is the main driver of mitochondrial electron trans-
port chains and hence, adenosine triphosphate (ATP) generation.
Lactate is generated from pyruvate by the action of LDH. Impor-
tantly, this reaction also converts NADH to NAD+. Normally, cells
maintain a tight balance between NAD+ and NADH, the cellu-
lar redox status. Hence, the balance of lactate and pyruvate in the
extra-cellular fluid, the LPR, reflects the redox status inside the cell
which in turn reflects the balance between non-oxygen consuming
glycolytic metabolism and oxidative mitochondrial metabolism.
The LPR increases if oxidative mitochondrial metabolism reduces
due to either hypoxia and/or mitochondrial damage. Glutamate
and glycerol are indirectly related to energy metabolism, as both
are biosynthesized from products of glucose metabolism. In the
context of brain injury, observed extra-cellular increases in glu-
tamate and glycerol are thought to reflect excitotoxicity and cell
membrane breakdown, respectively.
Temporal changes in microdialysate glucose concentration
might serve a useful biomarker after brain injury. Microdialysate
glucose concentrations reflect the balance between glucose delivery
and utilization; a fall in concentration indicates reduced delivery
and/or increased utilization. Several studies have found an associ-
ation between glucose concentrations and outcome with averaged
glucose concentrations lower in those patients with poor out-
come after SAH or TBI (56–58). In the largest study to date of
microdialysis in TBI patients, a multivariate logistic regression
model found that total monitoring averaged glucose was actu-
ally a positive predictor of mortality such that higher averaged
glucose concentrations predicted death (8). Regarding temporal
trends in individual patients’ glucose concentrations, Vespa et al.
observed three patterns of daily mean glucose in 30 patients with
severe TBI (59). Patients with a good outcome were found to have
initially normal glucose concentrations (0.5–1 mmol/L) that later
declined, as opposed to glucose concentrations that were low or
variable from the start of monitoring (59). Other authors have also
observed patterns of declining glucose in brain-injured patients
with time (8, 35).
The situation for glucose concentrations versus clinical out-
come is thus complex and still remains poorly understood. A likely
explanation is that there may be an optimal range of brain extra-
cellular glucose concentrations, and that levels below and above
this range are detrimental. Moreover, circulating glucose levels in
blood presumably influences brain extra-cellular glucose concen-
trations. While optimal glucose ranges have yet to be established
with certainty, existing evidence, albeit from a small study, sug-
gests that blood glucose levels within the range of 6–9 mM and
brain microdialysate glucose levels of 1–5 mM were associated
with minimizing the corresponding brain microdialysate LPR and
glutamate concentration, while microdialysate glucose levels <1
and >5 mM were associated with high LPR and high glutamate,
respectively (60). Firmer evidence for optimal glucose ranges may
emerge from the large datasets that continue to accrue in major
centers, as well as from more specialized studies involving labeled
glucose and scanning technologies.
Elevated lactate and an elevated LPR have both been associ-
ated with worse outcomes after both TBI and SAH (8, 57, 58,
61–63). However, there is again not a straightforward linear rela-
tionship between the concentration of lactate, the adequacy of
energy metabolism and clinical outcomes. Increasingly recog-
nized is the use of lactate as an energy substrate by the brain
particularly after injury (11, 64). Hence, the extra-cellular con-
centration of lactate reflects both the balance between substrate
delivery and utilization, and increased generation due to hypoxia
and/or a shift in metabolism away from mitochondria (11, 61).
The LPR perhaps better represents the energy status of cells and
has been found in several studies to discriminate between outcome
groups (8, 56, 63, 65).
Glutamate concentrations that increase over the course of the
monitoring period are associated with worse outcomes in TBI
patients (66). Glutamate concentrations have also been associated
with the development of delayed ischemic neurological deficits
(DIND) after SAH (67, 68) and outcome at 12 months after SAH
(69). Similarly, some studies have found an association between
glycerol and outcome (70, 71).
Individual microdialysis parameters are not 100% specific for
derangements in energy metabolism; different combinations of
microdialysate markers have been used in an attempt to better
predict clinical course and outcomes. In poor-grade SAH patients,
a combination of a LPR> 40 and glucose< 0.7 mmol/L was asso-
ciated with death or severe disability using logistic regression (72).
In severe TBI patients, the combination of a LPR> 25 and glu-
cose< 0.8 mmol/L was a strong predictor of poor outcome using
a multivariate model (73). Microdialysis parameters have also been
combined with other physiological measures, such as brain tissue
oxygen, to improve their predictive power (74).
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There are some important limitations of using microdialysis to
follow energy biomarkers after brain injury. Firstly, microdialysis
is an invasive technique and so limited to those patients suffering a
severe brain injury but not those with milder forms of injury. Sec-
ondly, microdialysis data can show a high degree of both between
and within patient variability, which is masked by studies that use
averaged data. Nelson et al. found microdialysis markers in 90 TBI
patients to be highly auto-correlated such that subject identity
alone (and not CPP, ICP, or outcome) explained 52-75% of the
variance in microdialysis data (75). Thirdly, microdialysis allows
the sampling of small extra-cellular molecules up to 100 kDa in
size and so any larger biomarkers of energy metabolism would not
be detected.
Complementary to extra-cellular measures of brain chemistry
is in vivo magnetic resonance spectroscopy (MRS), which mea-
sures brain tissue chemistry (see later section entitled In vivo
Biomarkers of Brain Chemistry).
SERUM BIOMARKERS OF ENERGY METABOLISM
Tracking cerebral energy metabolism by measuring substances
outside of the central nervous system (CNS) is challenging due
to the non-specific nature of the substrates and enzymes involved
in energy metabolism and due to the BBB limiting substances pass-
ing from the brain to the circulation. One substance that has been
identified as a marker of brain injury and which relates to cere-
bral energy metabolism is neuron-specific enolase (NSE). Enolase
is one of the enzymes essential for glycolysis, catalyzing the con-
version of 2-phosphoglycerate to phosphoenolpyruvate. Several
enolase isoforms have been identified including NSE, which is
thought to localize specifically to the cytoplasm of neurons and has
attracted interest as a potential serum biomarker for brain injury.
Several studies have demonstrated the value of serum or CSF NSE
levels in predicting pathological changes on head CT, although
NSE levels are not as specific or as sensitive as S-100 calcium bind-
ing protein B [S-100B, a multifunctional protein produced mainly
by astrocytes (76)] or glial fibrillary acidic protein [GFAP, an
cytoskeletal intermediate filament protein with multiple functions
(77)], evaluated as markers in TBI patients’ serum (78–81).
In terms of brain energy supply, serum glucose concentration
has received the most attention. For example, in a database of 327
TBI patients‘ admission blood parameters, hierarchical log linear
analysis revealed that age, raised serum glucose (>7.1 mmol/L),
low hemoglobin, and GCS, each had a direct independent statisti-
cal relationship with clinical outcome (82). Control of serum glu-
cose during on-going neurocritical care is achieved using insulin,
and there has been debate about whether tight or looser glycemic
control is better. Recent opinion is in favor of the looser control, as
exemplified by the findings of a detailed crossover study in 13 TBI
patients monitored by 18F-fluorodeoxyglucose (FDG)-positron
emission tomography (PET) scans and brain microdialysis (83).
In that study, there were more frequent critical reductions in
microdialysate glucose and elevations of microdialysate LPR dur-
ing tight glycemic control. We have already mentioned (above)
another small study in which blood glucose levels of 6–9 mM
and brain microdialysate glucose levels of 1–5 mM were asso-
ciated with optimal brain microdialysate chemistry (60). While
the underlying mechanisms interlinking serum glucose with brain
chemistry and physiology are still not fully understood, a very
recent study in 86 TBI patients has indicated an interesting asso-
ciation between increasing serum glucose levels and increasing
cerebrovascular PRx (84). The issue of management of blood glu-
cose levels after brain injury, and the twin problems of hypo-
and hyper-glycemia have been highlighted in a recent review (85).
Besides glucose, recent evidence has also suggested that circulating
lactate may be able to play a role as an alternative or supple-
mentary source of fuel for the human brain, see for example TBI
patient studies of endogenous lactate (11) and exogenous lactate
intravenous administration (64). However, this is a topic of much
controversy (86, 87).
BIOMARKERS OF BRAIN STRUCTURAL IMAGING
Computed tomography is the imaging modality of choice in the
acutely unwell injured brain due to its speed and relative ease
of imaging critically ill patients, particularly with the advent of
mobile machines which allow for imaging within the intensive
care unit itself. However, while useful in the detection of cerebral
edema, blood, and large lesions, it is clear that CT greatly underes-
timates the extent and distribution of injury after brain injury and
correlates poorly with outcome. Issues including the requirements
for MRI compatible equipment, and the logistical issues of trans-
porting critically unwell patients to the MRI suite mean that CT is
likely to remain the modality of choice in the acute phase. How-
ever, in contrast to many of the biomarkers used in neurointensive
care, MRI offers a unique opportunity for in vivo assessment of
the entire brain.
Magnetic resonance imaging is increasingly being used in
the context of TBI. Examples are shown in Figure 2. Conven-
tional MRI sequences (which include T1- and T2-weighted, fluid-
attenuated inversion recovery (FLAIR; good for the detection of
edema) and gradient recalled echo (GRE; for the detection of blood
products) have been clearly shown to be better than CT for the
detection of lesions, particularly traumatic axonal injury (TAI),
posterior fossa lesions, and brainstem lesions (88). Yet despite
improved lesion detection, many patients, particularly at the mild
end of the spectrum, have no abnormalities seen on CT or conven-
tional MRI, but still experience significant neurocognitive sequelae
following TBI. Even in the more severely injured patients, the
distribution of lesions detected are also often not sufficient to
explain the deficits seen. Persistent symptoms may be the result
of subtle microstructural alterations, such as TAI, which is often
demonstrated at post-mortem neuropathology, which lie below
the threshold of detection and are hence not demonstrated by
conventional imaging during the patient’s life (89, 90).
Despite the complexity, in vivo characterization as offered
by advanced MRI techniques offers the potential not only for
improved detection of the extent and distribution of injury but
also may allow for a unique in vivo window into some of the
pathophysiological processes that occur after TBI. Diffusion ten-
sor imaging (DTI) offers the most promise to help disentangle the
complexities of the anatomical basis of neurotrauma, and has been
shown to allow the exquisite delineation of the burden of injury,
particularly TAI. The diffusion tensor characterizes the magni-
tude of water diffusion [apparent diffusion coefficient (ADC)],
its directional non-uniformity (anisotropy), and its orientation
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FIGURE 2 | Example of an early contusion in a 49-year-old male
who sustained a severeTBI after an alleged assault. He was
GCS 4 at the scene. Imaging was performed approximately 48 h
after injury. A left frontal contusion can be clearly seen on the FLAIR
image. The apparent diffusion coefficient map (ADC) shows a
cytotoxic rim (red arrow) and vasogenic rim (yellow arrow). The
combined fractional anisotropy and directional map (FA) shows loss
of fibers integrity at the site of the contusion. Color hue indicates
direction as follows; red, left–right; green, anteroposterior; blue,
superior–inferior.
(eigenvalues). The exact mechanisms of the nature of water diffu-
sion in both gray and white matter are incompletely understood,
however the organization of tissue structure including the presence
of myelin, microtubules, and organelles, as well as the contri-
bution of intra- and extra-cellular water play a significant role.
Susceptibility-weighted imaging (SWI) (see below) is increas-
ingly being used as it is exquisitely sensitive to the presence of
blood products and improved the detection of micro-hemorrhages
secondary to shearing forces.
It is becoming apparent that the timing of MRI is important
after brain injury, particularly when being used as a prognostic
biomarker. In moderate-to-severe TBI, the number and volume
of lesions detected on FLAIR, gradient echo (GE), and diffusion
weighted imaging (DWI) decreased over time in patients imaged
at a median of 7 days, 3 months, and 12 months (91). The number
of DWI lesions and FLAIR lesion volume in the early MRI were
associated with outcome, indicating that early MRI is important
for questions of prognosis. A multi-national study [Neuro Imaging
for Coma, Emergence Recovery, Consortium (NICER)] investigat-
ing DTI parameters in patients who remain in a coma after the first
week of intensive care, shows promise for the prediction of poor
versus good outcome (92).
There are relatively few studies in humans investigating the
hyper-acute (within 72 h) and acute phases of TBI. In patients
with moderate-to-severe head injury imaged at a median of 32 h
after injury, fractional anisotropy (FA) was decreased in the white
matter predominantly as a result of increased radial diffusivity
consistent with edema (93). In patients with contusions, three dis-
tinct regions are seen within the first 72 h; a core of restricted
diffusion, surrounded by an area of raised ADC (likely vaso-
genic edema) and a thinner rim of reduced ADC (likely cytotoxic
edema), which is subsumed by the vasogenic rim after 72 h. This
outer cytotoxic rim may represent a “traumatic penumbra” that
may be rescued by effective therapy.
Imaging performed in the sub-acute or chronic stages after
TBI typically find consistent reductions in FA in classical areas
affected by TAI, even when conventional MRI shows no lesion.
These regions include the sub-cortical white matter in the frontal
and temporal regions, splenium of the corpus callosum, poste-
rior limb of the internal capsule, the cerebral peduncles, and
whole brain white matter. A recent meta-analysis concentrating
on mild TBI studies by Aoki and colleagues found a decrease in
FA and increase in ADC in the corpus callosum (and in particu-
lar the splenium) (94). The global nature of abnormality found
in what often appears to be structurally normal appearing tis-
sue is underpinned by a study that relates DTI abnormality to
the full spectrum of outcome, ranging from the vegetative state
to those with minimal or no disability. Here DTI abnormali-
ties in a broad range of regions were noted to scale with clin-
ical outcome (95). A more detailed discussion of the reported
DTI literature in TBI is provided in a review by Hulkower and
colleagues (96).
A relatively recent MRI development is SWI, which shows
promise for imaging the cerebral vasculature, micro-bleeds, iron
deposition, and calcification. SWI has been applied clinically in
TBI and other brain pathologies (97, 98). While SWI does not
replace conventional MRI modalities, it can provide potentially
valuable complementary information that moreover may prove
useful in clinical interventional trials (97, 98).
It is clear that dynamic changes able to be detected by imag-
ing are not confined to the hyper-acute stage (99, 100). Using
advanced MRI techniques to improve our knowledge of longitu-
dinal patterns of change in patient populations is important. Not
only will it aid the interpretation of imaging findings in individu-
als, but may also provide further insight into late pathophysiology,
help select appropriate patients for clinical trials, and provide a
framework that allows MRI to be used as an imaging biomarker
of therapy response.
www.frontiersin.org February 2015 | Volume 6 | Article 26 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carpenter et al. Brain injury biomarkers
In comparison to TBI, there has been relatively little research
in the use of MRI as a biomarker after SAH. In part this may part
be secondary to the technical difficulties of performing MRI in
patients with extensive extra-vascular blood products and the need
to ensure that any clips and coils are MRI safe. The presence of such
clips causes artifacts that may impact image quality (101). A recent
study has found cerebral micro-bleeds (on T2* GE) related to the
presence of DWI lesions in almost 46% of patients imaged within
7 days of ictus (102). The clinical significance of such lesions is
unknown. In poor-grade SAH patients, DWI within 96 h of ictus
multifocal areas of ischemia can be seen (103). In patients who
do not experience re-rupture, the presence of parenchymal lesions
with 24 h was associated with poorer outcome (104). However, the
numbers of patients looked at with such techniques are small and
much larger studies are required. Diffusion-perfusion mismatch
may be seen (105, 106). However, it may be technically difficult in
the presence of large amounts of blood products and it has not
been compared to other methods including transcranial Doppler
(TCD) ultrasonography or Perfusion CT.
Magnetic resonance imaging, including advanced sequences,
clearly has much to offer in the detection of injury, the prediction
of outcome, and greater understanding of the pathophysiology
processes that occur after a brain injury. It is likely that it will be
increasingly used in the acute and sub-acute phases of injury to
help answer key clinical questions.
IN VIVO BIOMARKERS OF BRAIN CHEMISTRY
Magnetic resonance spectroscopy in vivo can be used to explore
cellular metabolic status and evidence of cellular injury and so
may provide important insights into the complex biochemical and
pathophysiological processes after TBI. However, it can be tech-
nically difficult to obtain robust spectra and it is only relatively
recently that whole brain techniques have become available (107).
The majority of studies have studied mild TBI and/or long-term
injuries and used a limited number of (or single) voxels, using 1H-
MRS. Within 8 h of injury a reduction of N -acetylaspartate (NAA)
is apparent (108), and may return to normal levels in patients who
make a good recovery (109). In 10 moderate-to-severe TBI patients
imaged 48–72 h post-ictus, NAA (a marker of neuronal damage)
ratios were found to be decreased and in 5 patients lactate was
increased (17) (see Figure 3 for examples). The NAA and lactate
levels correlated with GCS at presentation and 3 months Glas-
gow outcome scale score (GOS) and which suggests early imaging
may be important for prediction. Preliminary studies suggest that
1H-MRS may also be informative about outcomes, with studies
finding it may discriminate between those who die or remain in
a vegetative state compared to those who recover awareness (110–
112). However, the best timing of scans, and optimal positioning
of spectroscopy voxels (if whole brain methods are not used) is
not yet determined. A more detailed consideration of the aspects
of brain chemistry that can be addressed by 1H-MRS as well as by
31P and 13C MRS is detailed below.
PRACTICAL CONSIDERATIONS FOR ACQUISITION OF IN VIVO SPECTRA
Besides providing images of the brain, magnetic resonance enables
a chemical signature (spectrum) to be determined for the regions
of interest (ROI). The nuclei that can be addressed by MRS at the
endogenous level (without administering exogenous label) are 1H
and 31P. These spectra can be obtained with either a surface coil or
head-coil. 31P MRS can be performed with or without 1H decou-
pling, and the 1H channel of the coil provides “scout images” for
visualizing brain anatomy and setting voxels (3-dimensional grid)
for selection of ROIs. MRS is achievable for endogenous 1H and
31P because these nuclei possess high natural abundance (99.985
and 100%, respectively). In contrast, 13C, the magnetic resonance-
responsive isotope of carbon, has a natural abundance of only
1.1%, while the most abundant carbon isotope is 12C (98.9%) that
is not itself magnetic resonance-responsive. Therefore, 13C MRS
requires large amounts of 13C-labeled substrates to be infused
intravenously or given orally. Also, 13C MRS is currently limited
to surface coils, because of the radio-frequency power absorption
by the brain as a consequence of decoupling 1H from the 13C to
achieve an interpretable 13C spectrum. The specific absorption
rate (SAR) limit to minimize heating of tissue is especially critical
with regard to the eyes and so 13C MRS is done using surface coils
to address ROIs of the brain avoiding the eyes. Any future design
of 13C MRS head-coils would thus necessitate adopting a partial
head-coil architecture avoiding the eyes.
Only a few centers worldwide have neurocritical care units
adjacent to MRI scanners equipped for MRS and the expertise
to support fully ventilated severe TBI patients through the pro-
cedure. Another hurdle to MRI/MRS of such patients is that they
often have intracranial monitoring probes, e.g., for ICP and PbtO2,
and in some cases microdialysis. In many cases, MRI/MRS is pos-
sible with these probes kept in situ but with the connecting leads,
tubing and pumps disconnected for the duration of the scan.
Such probes have to be tested beforehand (without the patient)
with the relevant MR coils, to ensure that they do not produce
undue heating (113–115). Another difficulty is the physical size,
shape, and location of the intracranial probes themselves, which
limits the positioning of surface coils and makes use of conven-
tional “birdcage” head-coils difficult. A way round this problem
is a birdcage-clamshell design (e.g., Figure 4) that opens up to
facilitate use with patients who have intracranial probes.
Consequent to the above constraints, the majority of human
brain MRS data thus comes from healthy adult volunteers and
those patients who are sufficiently well to be brought easily to
the scanner. These include various brain conditions (e.g., neu-
rodegenerative diseases and psychiatric disorders) and a smaller
number with mild TBI. Much of the wider MRS literature focuses
on tumors in various organs in cancer patients, and muscle in
healthy individuals and patients with “metabolic” diseases (e.g.,
diabetes).
BIOMARKER FEATURES OF THE IN VIVO SPECTRA
The most commonly used form of in vivo spectroscopy is 1H-
MRS (for examples see Figure 3). The most abundant signal
in the brain 1H spectrum is usually NAA. The peptide N -
acetylaspartylglutamate (NAAG) is a product of NAA and the
two are inter-convertible. NAAG is a small peak in the brain
1H-MRS that is difficult to distinguish from NAA. Often both
are considered together as “total NAA” that is usually interpreted
as a marker for health, viability, and/or number of neurons,
particularly their mitochondria. Reduction in NAA is regarded
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FIGURE 3 | Proton magnetic resonance spectra and conventional
magnetic resonance images showing the volume of interest for
spectroscopic imaging of a normal control (left panel), Patient 1 (central
panel), and Patient 8 (right panel) with traumatic brain injury (TBI) (17).
On conventional MRI, Patient 1 shows a focal hematoma in the frontal left
hemisphere and Patient 8 shows diffuse MRI abnormalities. Spectra show
decreases of N -acetylaspartate (NAA) and increases of choline (Cho) and
lactate (La) in patients with TBI (a and b in central and right panels) with
respect to the normal control (a in left panel). The spectra of Patient 1 (central
panel) show more pronounced metabolic abnormalities than those of Patient
8 (right panel), despite the fact that Patient 8 showed markedly more
abnormalities on conventional MRI. In the spectra of Patient 1 (central panel),
metabolic abnormalities are clearly evident in the normal appearing brain.
Finally, in Patient 1, voxels inside the focal hematoma (c in central panel) were
excluded to avoid the artifacts that could be derived by the cerebral
hemorrhagic contusion. Cr, creatine [Reproduced from J Neurol Neurosurg
Psychiatry, Marino S, et al. 78:501–7 (2007) with permission from BMJ
Publishing Group Ltd (17)].
FIGURE 4 | (A) Example of 31P MRS in brain of healthy volunteer
(male, 57 years). Signals detected are phosphocreatine (PCR), alpha-,
beta-, and gamma-ATP (a-ATP, b-ATP, g-ATP), inorganic phosphate (Pi),
phosphatidylethanolamine (1), phosphatidylcholine (2),
glycerophosphoethanolamine (3), and glycerophosphocholine (4), in a
3 cm×3 cm×3 cm voxel, on a Siemens Verio 3-T MRI scanner using
a bespoke PulseTeq birdcage/clamshell 31P head-coil illustrated
in (B). The head-coil opens up along the joins (gray), designed to
facilitate use with patients. Images are courtesy of the Wolfson Brain
Imaging Center.
as indicating dysfunction (permanent or temporary) of neu-
ronal tissue. Other 1H signals include creatine [combined signal
from creatine and phosphocreatine (PCR)], choline-containing
molecules, myo-inositol, glutamate, and glutamine (often consid-
ered together as Glx as the two species’ signals are incompletely
resolved), gamma-aminobutyric acid (GABA), and lactate.
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For a molecular species to be detected on 1H-MRS, it has to be
present at millimole per liter concentrations and also be mobile
(i.e., free to tumble rapidly–not bound to or closely confined by
membranes or macromolecules). Given these caveats, 1H-MRS
detects total intra- plus extra-cellular molecules. The intracellular
environment dominates the brain volume – it has been estimated
that the brain extra-cellular space between cells only comprises
about 20% of the total brain volume (116–118). Brain MRS thus
appears predominantly to reflect the intracellular compartment
and the measures are thus complementary to the extra-cellular
measures obtained by microdialysis (see earlier section entitled
Extracellular Markers of Brain Chemistry). For example, lactate
that is abundant extracellularly (at millimole per liter concentra-
tions) is much less evident on 1H-MRS of normal or TBI brain.
Moreover, depending on the choice of echo time (TE), these small
lactate signals can virtually disappear or appear inverted. Inter-
pretation of lactate is further complicated by overlap with lipid
signals. Thus, some 1H-MRS studies of normal and TBI brain do
not consider lactate at all, e.g., Ref. (119). Although lactate is a nor-
mal component of energy metabolism, if lactate appears elevated
in a tissue on 1H-MRS it is usually a sign of pathology, e.g., in
tumors. In TBI, lactate elevation can be seen on 1H-MRS in some
but not all instances, illustrated in Ref. (17).
Gamma-amino butyric acid, which has very low (usually
<1µmol/L) extra-cellular concentration, shows up as a 1H-MRS
signal reflecting its much higher intracellular concentration, e.g.,
1 mMU (120). MRS-detectable GABA likely reflects cytosolic
GABA, as the portion of intracellular GABA that is bound in vesi-
cles is thought to be less readily detectable by 1H-MRS, and the
same applies to glutamate.
Because of the difficulties in calibrating in vivo spectra, 1H-
MRS results are usually expressed as a ratio, e.g., NAA ratio to
creatine. In some studies, absolute concentrations of metabolites
have been presented by means of comparing the in vivo signals
to those of an artificial “phantom” – a large (e.g., 2 L) spherical
container of known concentrations of the metabolites of interest
in a “physiological” solution, e.g., Ref. (121). Total creatine is gen-
erally regarded as a marker of health in all types of brain cells and
its levels appear fairly constant in the absence of pathology. How-
ever, the creatine signal may increase or decrease in pathological
conditions, e.g., ischemic stroke and brain trauma (122, 123). The
brain 1H-MRS signal from choline is attributed predominantly
to free choline, acetylcholine, and cytidine diphosphate choline,
which are all “mobile,” rather than the more abundant choline-
containing phospholipids that are not freely mobile as they are
present in myelin and cell membranes so contribute less signal
(124). The 1H-MRS signal for choline is interpreted as a measure
of cell density and/or rate of membrane turnover or breakdown
(124). Myo-inositol interpretation in brain 1H-MRS is somewhat
debatable, often being regarded as a glial marker but lacking true
specificity (124). 1H in vivo MRS in TBI clinically in patients
(Figure 3) and in animal models have suggested NAA as the best
biomarker, often expressed as a ratio to creatine, or sometimes to
choline (17, 125).
31P MRS is less commonly performed than 1H-MRS, and
requires a dedicated coil (31P surface coil or 31P head-coil). 31P
MRS is typically used to measure ATP in tissues, including human
brain (Figure 4). While absolute ATP concentration is difficult
to measure in vivo in human brain, the ratio of PCR to γ-ATP
is a well-recognized measure of energy status. A high PCR/ATP
ratio is usually interpreted as good energy status of the tissue, with
“store species” PCR being well-stocked relative to “active” species
ATP. However, somewhat lower PCR/ATP ratios are not neces-
sarily harmful per se, but in some cases can be a physiological
adaptation, e.g., shown in human heart muscle (126). The ratio
of PCR to inorganic phosphate (Pi) is another recognized ratio.
Similar to the interpretation of PCR/ATP ratio, a high PCR/Pi
ratio is regarded as indicative of good energy status, although the
small area under the Pi peak is not easy to measure (integrate)
accurately. A more sophisticated 31P MRS method of quantify-
ing tissue energetics is measurement of ATP inter-conversion with
ADP by 31P-magnetization transfer techniques, including in vivo
saturation transfer (127). This is technically very challenging and,
moreover, it has a similar limitation to the simpler PCR/ATP
ratio, being unable to ascertain whether the apparently “good”
production of ATP is simply due to a lot of glycolysis (“anaero-
bic” metabolism, probably by glia) that is presumed less favorable
than mitochondrial energy metabolism (TCA cycle and oxidative
phosphorylation by neurons). Multi-parametric, complementary
analytical techniques, in addition to 31P-magnetization transfer,
are therefore needed to more fully characterize oxidative function
and mitochondrial metabolism in vivo (127). Much debate still
exists on this matter.
Another parameter that 31P MRS can measure is tissue intracel-
lular pH, based on the difference in chemical shift (in parts per mil-
lion) between Pi and PCR (18, 128). Studies of a TBI model, fluid
percussion injury in rats, with in vivo MRS of brain pre-injury and
at a range of time-points up to 8 h post-injury suggest a transient
intracellular pH decrease (31P), lowest at 40 min then recovering,
alongside an initial fall in PCR/Pi ratio (31P) at 40 min followed
by a temporary rise and subsequent overall decline, and a tran-
sient lactate increase (1H) peaking at 40 min then subsiding (129,
130). In TBI patients, brain intracellular pH measured by in vivo
31P MRS was reported as slightly higher than in control subjects
(131). The relationship between intra- and extra-cellular brain pH
is unclear. Extra-cellular brain tissue pH has been measured in TBI
patients using the Neurotrend multi-parameter probe (Codman,
Raynham,MA). This study suggested lower extra-cellular brain pH
in those TBI patients who ultimately did not survive, compared
with ultimate survivors (132). Moreover, occurrence of low extra-
cellular pH was a significant discriminator of ultimate mortality
in TBI patients, despite normal brain tissue oxygen concentration,
in a prospective study (133). Although these results look promis-
ing, the Neurotrend sensor is no longer manufactured, and there is
currently no commercially available clinical intracranial pH probe.
The relationship between intra- and extra-cellular brain pH is thus
likely to remain uncharted for the foreseeable future. Nevertheless,
there is scope for further investigating use of 31P in vivo MRS to
evaluate brain intracellular pH in TBI patients.
13C in vivo MRS has been mostly used to evaluate the TCA cycle.
The most commonly used substrate is intravenous 1-13C-glucose.
Besides the glucose itself, the major labeled signals detected are
for glutamate plus smaller signals for glutamine (sometimes
considered together as Glx) and minor signals for aspartate.
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Mathematical modeling of the kinetics of glutamate and gluta-
mine labeling enables the TCA cycle flux to be calculated. Other
species detectable in 13C in vivo MRS include GABA,glycerol,myo-
inositol, creatine, choline, NAA, lactate, alanine, and bicarbonate.
Other 13C-labeled substrates that have been employed include 1,6-
13C2 glucose, 2-13C glucose, and 2-13C acetate (134). The latter is
regarded as a glial substrate, whereas glucose is a fuel for both
neurons and glia.
Besides directly observed 13C MRS, an alternative approach
is indirect observation of 13C via the 1H spectrum, termed
1H-observe [13C-edited] spectroscopy, or proton-observe carbon
edited (POCE) spectroscopy. The advantages of POCE are that 1H-
MRS is inherently more sensitive than 13C MRS and that POCE
directly gives 13C fractional enrichment values (134). However, a
disadvantage is that the indirect (POCE) modality is more com-
plicated to perform and interpret than directly observed 13C MRS.
Part of the difficulty is that the 1H spectrum has a relatively narrow
x-axis frequency scale (parts per million), and moreover many of
the signals are multiplets due to spin couplings with neighboring
protons, so the spectrum contains complex, overlapping signals,
making accurate de-convolution a challenge.
EX VIVO NMRMEASUREMENTS OF BRAIN EXTRA-CELLULAR
MOLECULES
High-resolution nuclear magnetic resonance (NMR) spectroscopy
can be used ex vivo to characterize extra-cellular molecules from
the brain, sampled using microdialysis. Characteristics of micro-
dialysis are that it is selective for hydrophilic molecules< 100 kDa
the extra-cellular fluid, and is very focal; it can be done with a
brain tissue oxygen sensor in proximity, plus an ICP probe.
Microdialysis is good for measuring lactate, which predomi-
nantly shows up extracellularly (see section on Energy Biomarkers
above), whereas lactate is often difficult to measure in brain tis-
sue using in vivo MRS (see section on MRS Biomarkers above).
Microdialysate lactate (endogenous) is usually quantified using
enzymatic colorimetric assays on a bedside analyzer (CMA600 or
ISCUS). Besides lactate, microdialysis can sample other endoge-
nous extra-cellular molecules. Also, labeled substrates (e.g., 13C)
can be administered directly into the brain extra-cellular space via
the microdialysis catheter. Brain cells can take up these substrates,
and the metabolites that exit from the cells can be simultane-
ously collected via the same microdialysis catheter and analyzed
by high-resolution NMR in the laboratory (21, 135).
In contrast to the MRS techniques above which are “snap-
shots” for the duration of the scan, microdialysis is a continuous
flow technique. Microdialysates collected are analyzed in suitable
sample volumes depending on the assay required, e.g., hourly
for endogenous measurements (ISCUS/CMA600), or a 24-h pool
for 13C-labeling studies (13C NMR). In principle, shorter sam-
pling/pooling intervals could be achieved by adopting suitable
technology, e.g., a microcryoprobe on NMR. Mass spectrome-
try could also in theory be used for analyzing smaller (shorter)
sampling pools but at the expense of at least some informa-
tion on intra-molecular positions of label within the metabolite
molecules. Intra-molecular positions of label are diagnostic for
the metabolic pathways and so NMR is the “gold standard” for
deducing metabolic pathways in 13C-labeling studies.
INFLAMMATION BIOMARKERS
The brain has traditionally been considered as an immunologically
privileged site as a result of the blood–brain barrier, absence of a
lymphatic system, and lack of peripheral immune surveillance of
CNS antigens. However, innate inflammation is a highly conserved
process that is involved in all types of pathology and inflammatory
mediators such as cytokines and chemokines are increasingly rec-
ognized as mechanistic mediators of several CNS pathologies (16,
136). This has led to the investigation of these mediators as possible
biomarkers of injury or underlying pathological processes.
A number of cytokines and chemokines have been recovered
from blood, CSF, and microdialysate following TBI (16). Several
studies have attempted to correlate various clinical parameters
with these mediator levels in order to develop their use as biomark-
ers. Interleukin-1beta (IL-1b) is the prototypic pro-inflammatory
cytokines and has been measured in a wide range of cerebral
pathologies. In TBI, raised CSF concentrations of IL-1b have been
correlated to both increased ICP (137) and worsened outcome
(138). IL-1b has also been recovered from the brain extra-cellular
space using microdialysis. Moreover, the balance between IL-1b
and its endogenous antagonist IL-1 receptor antagonist have also
been related to dichotomized clinical outcome (139). In contrast,
raised IL-6 concentrations have been related to an improved out-
come in several studies (140–142). TNF has also been closely
investigated as a cytokine with potentially deleterious effects in
animal models; however no relationship could be found between
CSF TNF concentrations and either blood–brain barrier perme-
ability (143) or ICP (137, 144). CSF IL-8 has been found to
correlate with both increased blood–brain barrier permeability
(145) and mortality (146). However, plasma IL-8 was not found
to correlate with outcome (147).
Cytokines have also been measured following ischemic stroke.
Some studies have found a correlation with outcome such as
between plasma IL-6 and stroke severity (148) (increased levels
correlate with worse outcome) while others have found raised
levels of several plasma mediators such as IL-6, matrix met-
alloprotease 9 (MMP-9), and S-100B but no relationship to
outcome (149).
Taken together the evidence for cytokines as biomarkers is
often conflicting and inconsistent. There are several reasons why
cytokines may not be easily used as biomarkers. Firstly, the same
mediators may behave in a different fashion depending on the
exact context in which they are released (150–153). Secondly, there
are multiple interactions between cytokines that mean that the
cytokine milieu may impact on the action of any given biomarker
such that it is overly simplistic to simply classify a mediator as
damaging or protective (154). Thirdly, the time course over which
a cytokine is released in relation to injury has an important effect
on the concentration measured. Variations in sampling time can
result in widely differing measured concentrations as the absolute
levels can change by several orders of magnitude (16). Finally,
because of the complexity of cytokine cascades, many cytokines are
highly correlated between themselves making it difficult to infer
causality from observational studies, even when a cytokine appears
to predict a given clinical outcome (16, 155). Our view would be
that, as fundamental mediators of the underlying pathophysiol-
ogy, cytokine measurements are likely to be important biomarkers,
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however, a more nuanced approach to univariate correlations is
required that takes into account the multiple possible interactions
and utilizes panels of cytokines and patterns of expression (155).
Although not yet in widespread use, recent clinical research has
demonstrated the principle of using PET with (R)-11C-PK11195,
a ligand for activated microglia, to image neuroinflammation, fol-
lowing up patients in the months and years after TBI (14, 15). As a
result, it has been suggested that therapeutic interventions may be
beneficial for longer periods after trauma than previously assumed
(15). Greater availability of PET technology in future would facil-
itate the measurement of neuroinflammation and might offer a
useful guide to therapy.
CELL DEATH BIOMARKERS
In the hours and days following the primary injury, complex and
variable series of changes, including energy perturbations, inflam-
mation, and cell death, occur in the injured brain, leading to
further neurological impairment and mortality. Due to its delayed
nature, this secondary injury is potentially preventable. A goal of
TBI research is development and clinical validation of novel phar-
macological treatments to improve outcome. Studies using light
and electron microscopy, cell/tissue staining, and DNA fragmenta-
tion have been instrumental in illustrating cell death, by apoptosis
and necrosis, in cell and animal models of injury. However, they
offer only a snapshot of a complex evolving process. Apoptotic
cells can die and disappear within hours, so can be missed if the
cells or tissue is analyzed too early or too late. The continuous
drainage of CSF, often used to manage life-threatening intracranial
hypertension in TBI patients, presents an opportunity to mea-
sure biomarkers of cell death in the brain of human TBI patients
over periods of time. The changing levels of these biomarkers,
typically analyzed by ELISA or immunoblotting techniques, has
begun to shed light on time-dependent cell death in the brains of
TBI patients.
To summarize, biomarkers used to elucidate pathways of cell
death in human TBI patients, such as caspase-3 (156, 157), soluble
Fas (156, 158), cytochrome c (159–161), Bcl-2 (162), alpha II-
spectrin breakdown products (163), neurofilament cleavage prod-
ucts (164), and HMGB1 (159, 165) offer the possibility to probe
cell death pathways in human TBI patients. A particular biomarker
may identify a patient population that will be most susceptible to
a particular neuroprotective strategy (166). Most of the cell death
biomarker studies cited above have been in CSF, with the excep-
tion of Ref. (164), which was in brain microdialysates. The latter
technique provides better scope for continuous monitoring in TBI
patients, particularly as CSF is not always drained, and several of
the cell death biomarkers are under 100 kDa making them poten-
tially suitable for microdialysis. Better understanding of cell death
biomarkers may suggest ways to better manage patients and pro-
vide appropriate neuroprotective strategies at the most effective
times.
BIOMARKERS OF CEREBRAL CIRCULATION IN SAH
Advancement of understanding of the pathophysiology of SAH
has led to a considerable reduction in mortality (167). Factors
that exert the strongest effects on outcomes have been identi-
fied as: age, neurological grade on admission, amount of SAH on
admission CT,presence of intracerebral or intraventricular hemor-
rhage,aneurysm size and location,and presence of delayed cerebral
ischemia (DCI) (168, 169). These prognosticators have remained
unchanged since the 1990s. Nevertheless, new biomarkers of brain
injury are being investigated.
Aneurysm rupture leads to intracranial hypertension and tran-
sient cerebral circulatory arrest (170, 171). Clinically, this mani-
fests with depressed consciousness and is categorized using grad-
ing scales – currently the most important determinant of outcome.
However, cerebral ischemia is known to cause activation of several
key pathophysiological pathways, which may propagate primary
injury, as well as increase tissue vulnerability to secondary insults,
including DCI.
In excess of 40 different clinical scales have been described.
The most frequently used are the Hunt and Hess scale (172)
and the World Federation of Neurosurgical Societies scale (173),
which describe the level of consciousness and the presence of
neurological deficits (168, 169).
Imaging characteristics have always been an important tool
evaluating SAH. The amount of SAH on the initial CT scan is
known to be associated with development of DCI (however, less
so with overall outcome) (174). The first systematic scale grad-
ing subarachnoid blood load was described by Fisher et al. (174)
and remains to be the most widely used scale to date. Subse-
quently, numerous different classifications have been introduced
with the aim of refining the predictive power, although few of
these have added real clinical benefit and have not been as widely
implemented (175–177).
Besides blood load, other early imaging characteristics have also
been used for outcome prediction. Early CT perfusion has gained
interest as a predictor of DCI risk. However, while current evi-
dence supports CT perfusion for detecting DCI, the available data
does not uniformly demonstrate that early imaging has prognostic
value (178). Contrary to CT perfusion, early ischemia on MRI was
shown to be a poor prognostic factor (103). However, these find-
ings are hampered by small numbers, as well as by applicability
only to poor-grade patients. Another acute imaging characteris-
tic is global cerebral edema, present in up to 8% of patients on
the initial CT, and further 12% on subsequent imaging (179).
Patients with global edema have a higher incidence of cerebral
metabolic crisis in the initial 12 h (180), and have less favorable
outcomes (179).
Serial clinical examination is not possible in poor-grade
patients, hence the interest in invasive and non-invasive brain
monitoring techniques, including measurements of cerebral per-
fusion and ICP, venous oximetry (jugular bulb catheters), brain
tissue oxygen tension (PbtO2), microdialysis, continuous elec-
troencephalography (EEG), and TCD. Results are best interpreted
when assessed using multimodality brain monitoring protocols
(Figure 5). TCD is the most common neuromonitoring modality
used in SAH. Flow velocity and Lindegaard ratio are used to detect
vasospasm (181, 182). Although sensitive, only 50% of patients
with positive TCD have clinical symptoms. Most PbtO2 and micro-
dialysis data have been extrapolated from head injury. Despite the
lack of large scale studies, metabolic derangements are frequently
demonstrated in patients with SAH, in particular those with cere-
bral edema (180). Furthermore, decreased glucose, increased LPR
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FIGURE 5 | Example of monitoring and imaging data from a patient
with SAH (WFNS 5) with an AComA aneurysm, which was clipped on
day 2 post-ictus. Invasive monitoring probes including ICP and PbtO2, as
well as an EVD, were inserted on the right side on admission. During the
course of treatment, the patient developed cerebral vasospasm, which
was initially detected using TCD monitoring on day 3 post-ictus (black
arrow). Subsequent CTP on day 4 demonstrated a perfusion deficit in the
left ACA territory (second black arrow signifies the time CTP performed),
i.e., contralateral to the PbtO2 probe (importantly, the PbtO2 values were
within normal range at all times, i.e., >25 mmHg and further responded to
hypertension, rising to >30–35 mmHg). A further PbtO2 probe, targeted to
the area of perfusion deficit seen on CTP, was inserted (third black arrow
indicates time of insertion), which demonstrated lower/ischemic
(<15 mmHg) values of PbtO2 (purple color on graph). ACA, anterior
cerebral artery; AComA, anterior communicating artery; CTP, CT perfusion;
EVD, external ventricular drain; PbtO2, brain tissue oxygen; SAH,
subarachnoid hemorrhage; TCD, transcranial Doppler; WFNS, world
federation of neurosurgical societies scale.
as well as increased glutamate levels have been associated with DCI.
Microdialysis is able to predict DCI with 82% sensitivity and 89%
specificity (68). Similarly, frequent episodes of cerebral hypoxia
(PbtO2< 15 mmHg) have been shown to be associated with fatal
outcome (183). Importantly, metabolic derangement and hypoxia
are frequently not related to intracranial hypertension nor reduced
cerebral perfusion, supporting the need for multimodal monitor-
ing as well as routine imaging (184). Other experimental methods
include electrocorticography to detect cortical spreading depo-
larizations (SD), which when clustered can lead to an inverse
hemodynamic response, and thus hypoperfusion and hypoxia, and
tend to be related to DCI (185, 186). Despite these promising find-
ings and the wealth of pathophysiological information gained, the
use of monitoring in guiding management remains to be deter-
mined. In particular, the focal nature of DCI poses a challenge for
all focal monitoring modalities (Figure 5) (187).
Different modalities, such as TCD, PbtO2, and near-infrared
spectroscopy, have been used to assess the state of cerebral blood
flow autoregulation–a possible homeostatic mechanism, which is
thought to be affected following acute insult to the brain. The
theory of the importance of autoregulation is related to the pre-
sumed dual control mechanism of cerebral blood flow, whereby, in
physiological conditions, a single insult such as reduced cerebral
perfusion or vessel narrowing will not produce significant alter-
ations of blood flow due to autoregulatory compensation (188).
Loss of autoregulation in the first 5 days has been found to be
predictive of both unfavorable outcome as well as DCI (189, 190).
A number of biochemical compounds have been investigated
as potential markers of brain injury and; however, none have been
incorporated into clinical routine. Interestingly, investigated com-
pounds can be divided into those which are thought to signify
on-going brain damage/ischemia and those that are thought to
play a role in the pathogenesis of DCI. Hyponatremia has been
associated with cerebral infarction (191). The exact mechanism
remains unknown; nevertheless, some clinicians use it as a marker
of DCI. S-100beta is another compound that is known to indi-
cate brain injury, which increases in patients after SAH (192). A
recent study, looking at a panel of four markers of brain ischemia
(including S-100beta), sampled within 50 h of ictus showed good
predictive power for poor outcome (193). Others have studied
compounds, which are thought to play a role in the pathogenesis
of DCI. Notably, Endothelin-1 (ET-1), a potent vasoconstrictor,
has been shown to be a marker of DCI (194). However, admin-
istration of ET-1 receptor antagonists does not improve outcome
(195). Inflammation is thought to play an important role in brain
ischemia after SAH, suggesting pro-inflammatory cytokines could
be used as biomarkers as well as therapeutic targets. It has been
shown that early increases if IL-6, both in serum and CSF, are pre-
dictive of DCI (196, 197). However, it must be noted that these
findings may be contaminated by the presence of sepsis, which in
itself is a poor prognosticator.
Numerous methods of stratifying brain damage after SAH have
been investigated, ranging from clinical grading scales, through
imaging findings and invasive neuromonitoring modalities and
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finally to assessment of molecular biomarkers form serum and
CSF. However, despite the wealth of pathophysiological insight,
few methods have gained widespread clinical acceptance. Clini-
cal assessment with the use of grading scales remains the gold
standard for outcome prognostication and decision-making. Sim-
ilarly, DCI is diagnosed on the basis of neurological deterioration.
TCD, angiography as well as perfusion imaging remain useful
as confirmatory tools, while neuromonitoring, although showing
promise is limited to only a subset of patients and is hampered
by the focal nature of available probes. Further research is needed
before reliable biochemical markers are available for clinical use.
INTEGRATION OF BIOMARKERS FROMMULTIPLE
MODALITIES WITH DIFFERENT TIMESCALES
Important considerations in brain monitoring are those of
timescales and sampling frequency. Data from modalities such as
ICP, CPP, brain tissue oxygenation, pressure reactivity, etc., are cap-
tured at high rates–e.g., from 100 Hz to once per 10 s. The Nyquist
theorem (198) states that any time-variable modality should be
sampled at least two times more frequently than the maximal rate
of its expected changes. These sampling frequencies are thus with-
out doubt sufficiently fast to express any underlying pathological
changes whatever their timescale. In contrast, biochemical changes
are, of necessity, sampled much more slowly, e.g., brain microdialy-
sis routinely has hourly vial changes and readings, while samplings
of blood and CSF for analysis are typically twice a day. Further-
more, scans such as MRI and PET are “snapshots” done usually
just once or twice over the course of the patient‘s neurocritical
care. The question thus arises of how best to integrate data modal-
ities with such diverse time-bases. ICP and other rapid-sampling
data can be averaged, e.g., over 60-min periods, to put them on
an equal footing with the hourly microdialysis data for statistical
evaluation (8, 9). There is evidence to suggest that TBI patients‘
brain chemistry in many cases evolves relatively slowly; Nelson
et al. found that cerebral microdialysis data are often highly auto-
correlated even up to a future 30 h, but with weak correlation to
ICP and CPP (75) (also see earlier section entitled Extracellular
Biomarkers of Brain Chemistry). Thus, the dominant processes
monitored by microdialysis may be long-term, possibly spanning
days or longer, and arguably may be better related to scans than to
rapid changes evident from ICP and CPP, etc. A notable exception
regarding the speed of changes in brain chemistry may be in the
situation of SD where pre-clinical studies indicate rapid changes
in chemistry following propagation of the SD wave (199) or in
the case of seizures (200). The development of rapid/continuous
online detectors for microdialysis (199), as well as for blood and
CSF, may assist in getting a truer picture of temporal changes in
brain chemistry.
CONCLUSION AND FUTURE PROSPECTS
Here, we have reviewed many of the different types of biomark-
ers that are available, or potentially available, for monitoring the
human brain after severe acute traumatic and non-TBI. While
only a small number of these biomarkers are in routine use, and
then only in relatively specialized neurocritical care centers, there
is a much scope for more of the non-routine biomarkers to play
a role in clinical research studies to provide surrogate endpoints
in Phase II studies. The latter are typically in small numbers of
patients and are not statistically powered for clinical outcomes. In
such context, intelligent selection of biomarkers can provide useful
pointers toward efficacy at the biochemical level, which may assist
decision-making as to which agents and/or procedures are worth
pursuing into larger, much more costly and time-consuming Phase
III trials. Examples of biomarker methodology are summarized in
Table 1. Whether we need more biomarkers is an open question,
which may be partly answered by increased use of screening tech-
niques such as metabolomics and proteomics, which may help
identify hitherto unrecognized candidate biomarkers.
Better use of the biomarkers we have identified already is
certainly needed. Future advances in sensor technology such as
lab-on-a-chip and replacement of current invasive brain probes
with smaller, less invasive devices may help promote the monitor-
ing of biomarkers at the bedside. Even with existing technology,
part of the answer may be in advances in data handling methods,
including multivariate analysis and machine learning technolo-
gies, particularly those that address temporal patterns. An essential
foundation is the large databases that are continuing to accrue
in specialist centers and multi-center collaborations. Currently,
interpretations hinge on consideration of each of the parameters
in relation to “consensus” thresholds based on collective expe-
rience among clinicians, and such thresholds are often debated.
Furthermore, temporal patterns are usually evaluated visually. We
are reaching the stage when simply “eyeballing” complex mul-
timodal datasets may be insufficient to assess the true situation
and prospect for the individual patient. More objective evaluation
methods may enable better integration of time-variant, multi-
parameter data and piece together the jigsaw puzzle of complex
evidence to create an informative picture.
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